Literature DB >> 10991870

In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4.

N Rastogi1, K S Goh, M Berchel, A Bryskier.   

Abstract

The in vitro activities of HMR 3647 (telithromycin) and HMR 3004, two novel semisynthetic ketolides, were investigated and compared with that of the reference macrolide drug, clarithromycin, against 34 strains of slowly growing mycobacteria at pHs 6.8 and 7.4, as determined radiometrically. The MICs at pH 7.4 were about 1 to 2 dilutions lower than those observed at pH 6.8. In terms of the highest to the lowest activity, the three antibiotics could be classified as follows: clarithromycin > HMR 3004 > HMR 3647. Among the species tested, Mycobacterium bovis BCG, M. ulcerans, M. avium, and M. paratuberculosis were moderately susceptible to HMR 3004 and HMR 3647 (MICs at pH 7.4, < or =5.0 and < or =20.0 microg/ml, respectively, versus < or =1.25 microg/ml for clarithromycin), whereas M. tuberculosis, M. africanum, M. bovis, and M. simiae were resistant (MICs, > or =10.0 and > or =40.0 microg/ml, respectively, at pH 7.4). Although not more active than clarithromycin in vitro, the high level of intracellular accumulation of the two ketolides inside phagocytes warrants further screening in experimental animal models.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10991870      PMCID: PMC90161          DOI: 10.1128/AAC.44.10.2848-2852.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Effect of pH on radiometric MICs of clarithromycin against 18 species of mycobacteria.

Authors:  N Rastogi; K S Goh
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

2.  In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine).

Authors:  J E Hoppe; A Bryskier
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

3.  Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004).

Authors:  L M Ednie; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

4.  Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans.

Authors:  E J Goldstein; D M Citron; S Hunt Gerardo; M Hudspeth; C V Merriam
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

5.  Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens.

Authors:  A Denis; C Agouridas; J M Auger; Y Benedetti; A Bonnefoy; F Bretin; J F Chantot; A Dussarat; C Fromentin; S G D'Ambrières; S Lachaud; P Laurin; O Le Martret; V Loyau; N Tessot; J M Pejac; S Perron
Journal:  Bioorg Med Chem Lett       Date:  1999-11-01       Impact factor: 2.823

6.  In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages.

Authors:  N Rastogi; V Labrousse; K S Goh
Journal:  Curr Microbiol       Date:  1996-09       Impact factor: 2.188

7.  In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria.

Authors:  K Malathum; T M Coque; K V Singh; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

8.  The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection.

Authors:  F G Araujo; A A Khan; T L Slifer; A Bryskier; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

9.  Cellular accumulation of the new ketolide RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin.

Authors:  D Vazifeh; H Abdelghaffar; M T Labro
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

10.  Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol.

Authors:  N Rastogi; K S Goh; V Labrousse
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

View more
  13 in total

1.  Growth, Congo Red agar colony morphotypes and antibiotic susceptibility testing of Mycobacterium avium subspecies paratuberculosis.

Authors:  Nicole M Parrish; Chiew G Ko; James D Dick; Paul B Jones; Jay L E Ellingson
Journal:  Clin Med Res       Date:  2004-05

2.  Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics.

Authors:  Nicole Ritz; Marc Tebruegge; Tom G Connell; Aina Sievers; Roy Robins-Browne; Nigel Curtis
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

3.  Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible.

Authors:  Nadya Andini; Kevin A Nash
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

4.  In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis.

Authors:  Kanakeshwari Falzari; Zhaohai Zhu; Dahua Pan; Huiwen Liu; Poonpilas Hongmanee; Scott G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  Telithromycin.

Authors:  J A Balfour; D P Figgitt
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Structural and functional characterization of Rv2966c protein reveals an RsmD-like methyltransferase from Mycobacterium tuberculosis and the role of its N-terminal domain in target recognition.

Authors:  Atul Kumar; Kashyap Saigal; Ketan Malhotra; Krishna Murari Sinha; Bhupesh Taneja
Journal:  J Biol Chem       Date:  2011-04-07       Impact factor: 5.157

7.  Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice.

Authors:  A Bentoucha; J Robert; H Dega; N Lounis; V Jarlier; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

8.  Steady-state plasma and intrapulmonary pharmacokinetics and pharmacodynamics of cethromycin.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

9.  Susceptibility of Mycobacterium avium sbsp paratuberculosis to monensin sodium or tilmicosin phosphate in vitro and resulting infectivity in a murine model.

Authors:  Gordon W Brumbaugh; R Bruce Simpson; John F Edwards; Dwayne R Anders; T D Thomson
Journal:  Can J Vet Res       Date:  2004-07       Impact factor: 1.310

10.  Molecular basis of intrinsic macrolide resistance in the Mycobacterium tuberculosis complex.

Authors:  Karolína Buriánková; Florence Doucet-Populaire; Olivier Dorson; Anne Gondran; Jean-Claude Ghnassia; Jaroslav Weiser; Jean-Luc Pernodet
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.